Targeting metabolic plasticity in glioma stem cells in vitro and in vivo through specific inhibition of c-Src by TAT-Cx43_266-283.

ABSTRACT:

Background

Glioblastoma is the most aggressive primary brain tumour and has a very poor prognosis. Inhibition of c-Src activity in glioblastoma stem cells (GSCs, responsible for glioblastoma lethality) and primary glioblastoma cells by the peptide TAT-Cx43_266-283 reduces tumorigenicity, and boosts survival in preclinical models. Because c-Src can modulate cell metabolism and several reports revealed poor clinical efficacy of various antitumoral drugs due to metabolic rewiring in cancer cells, here we explored the inhibition of advantageous GSC metabolic plasticity by the c-Src inhibitor TAT-Cx43_266-283.

Methods

Metabolic impairment induced by the c-Src inhibitor TAT-Cx43_266-283 in vitro was assessed by fluorometry, western blotting, immunoflu

SUBMITTER: Pelaz SG 

PROVIDER: S-EPMC7708820 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature